AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20677606
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine 12.5 mg
Trial: 26578422
Drug: Brimonidine/timolol fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine/timolol fixed combination (BTFC)
Trial: 17571086
Drug: Unfixed combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfixed combination of brimonidine and timolol
Trial: 16648043
Drug: 5-aminolevulinic acid
RxNorm normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminolevulinic acid (20 mg/kg bodyweight)
Trial: 6382004
Drug: Cimetidine 200
RxNorm normalized name: cimetidine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 200 mg twice a day
Trial: 6382004
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg twice a day
Trial: 26804670
Drug: 5-alpha reductase
RxNorm normalized name: 5-alpha reductase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-alpha reductase inhibitors (5-ARIs)
Trial: 24607046
Drug: MP29-02, one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MP29-02, one spray per nostril twice daily (total daily doses of azelastine hydrochloride and FP were 548 mcg and 200 mcg, respectively)
Trial: 24607046
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP), 2 sprays per nostril once daily (total daily dose 200 mcg)
Trial: 22396230
Drug: Therapeutic hypothermia
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic hypothermia (TH) using cloth covered cooling gel packs for 72 hours
Trial: 20178792
Drug: Fibrin glue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin glue injections (n = 36)
Trial: 8701480
Drug: Inhalation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation therapy with magnesium sulfate
Trial: 8701480
Drug: Inhalation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation therapy with salbutamol sulfate
Trial: 6859073
Drug: Nitrates (large
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrates (large doses)
Trial: 6859073
Drug: Long-term nitrate
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term nitrate therapy
Trial: 26910903
Drug: MRI-guided laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI-guided laser interstitial thermal therapy (laser ablation)
Trial: 24744317
Drug: FA plus
RxNorm normalized name: Medorfa Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FA plus 30 mg of iron (IFA)
Trial: 24744317
Drug: FA plus
RxNorm normalized name: Medorfa Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FA plus 30 mg of iron (IFA) and FA, iron, plus 13 additional micronutrients (MM)
Trial: 22185768
Drug: Passive Movement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive Movement Therapy (PMT) three times a week for four weeks
Trial: 17492901
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment modalities for chronic pelvic pain
Trial: 15644655
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg twice daily
Trial: 4061020
Drug: Suxamethonium during
RxNorm normalized name: suxamethonium
DrugBank: Succinylcholine (DB00202)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suxamethonium during halothane inhalation in group I (children under 10)
Trial: 4061020
Drug: Suxamethonium during
RxNorm normalized name: suxamethonium
DrugBank: Succinylcholine (DB00202)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suxamethonium during halothane inhalation in group II (children over 10)
Trial: 4061020
Drug: Suxamethonium during
RxNorm normalized name: suxamethonium
DrugBank: Succinylcholine (DB00202)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suxamethonium during halothane inhalation in group III (children over 10)
Trial: 4061020
Drug: Pancuronium and
RxNorm normalized name: pancuronium
DrugBank: Pancuronium (DB01337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pancuronium and thiopentone during intravenous induction in group III (children over 10)
Trial: 30843873
Drug: Transcutaneous (t.c.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous (t.c.) administration of trivalent influenza vaccine (TIV)
Trial: 30843873
Drug: Intradermal (i.d.)
RxNorm normalized name: IOBENGUANE I 123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (i.d.) administration of trivalent influenza vaccine (TIV)
Trial: 30843873
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) administration of trivalent influenza vaccine (TIV)
Trial: 30538429
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of roflumilast (0.25, 0.375, and 0.5 mg)
Trial: 30538429
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of roflumilast (0.375 mg once daily for 11 days)
Trial: 27813422
Drug: BI 695501
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 695501 (40 mg subcutaneous dose)
Trial: 27813422
Drug: US-approved Humira
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-approved Humira (40 mg subcutaneous dose)
Trial: 27813422
Drug: EU-approved Humira
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EU-approved Humira (40 mg subcutaneous dose)
Trial: 19907167
Drug: Aspirin in
RxNorm normalized name: Non-Aspirin Infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin in combination with rt-PA thrombolysis
Trial: 17691590
Drug: Iron(III)‐hydroxide polymaltose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron(III)‐hydroxide polymaltose complex (IPC) administered with orange juice (enhancer)
Trial: 17691590
Drug: Iron(III)‐hydroxide polymaltose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron(III)‐hydroxide polymaltose complex (IPC) administered with food
Trial: 17691590
Drug: Iron(III)‐hydroxide polymaltose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron(III)‐hydroxide polymaltose complex (IPC) administered during fasting
Trial: 17691590
Drug: Iron(III)‐hydroxide polymaltose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron(III)‐hydroxide polymaltose complex (IPC) administered with black tea (inhibitor)
Trial: 11908739
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) as a single agent for three months
Trial: 10440409
Drug: Conventional dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dual or triple cyclosporine A immunosuppressive therapy
Trial: 7540478
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment (2 IU/M2) continued until variant GH production from the placenta was evident.
Trial: 7540478
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment (2 IU/M2) during pregnancy.
Trial: 29261736
Drug: Oral vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral vancomycin (250mg every 6 h for 10-14 days)
Trial: 24028842
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of a medical clown during intravenous catheter insertion
Trial: 24028842
Drug: Absence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absence of a medical clown during intravenous catheter insertion
Trial: 18987358
Drug: lenalidomide 10
RxNorm normalized name: lenalidomide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lenalidomide 10 mg/day
Trial: 21753188
Drug: lenalidomide 5
RxNorm normalized name: lenalidomide 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lenalidomide 5 mg/day
Trial: 9143888
Drug: Indirect laser
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect laser treatment (scatter photocoagulation)
Trial: 8191269
Drug: Propofol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (15 mg)
Trial: 8191269
Drug: Intralipid (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid (1.5 mg)
Trial: 31776882
Drug: Waitlisted-treatment-as-usual control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlisted-treatment-as-usual control group
Trial: 27405049
Drug: Self-care skills
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-care skills training with solution-focused counselling
Trial: 23252878
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg vortioxetine
Trial: 18464745
Drug: Irbesartan monotherapy
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irbesartan monotherapy for 12 weeks
Trial: 9048788
Drug: CDP571 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP571 (5 mg/kg)
Trial: 29360778
Drug: P280 (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P280 (70 g whey protein, 280 kcal)
Trial: 29360778
Drug: M280 (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M280 (14 g protein, 28 g carbohydrate, 12.4 g fat, 280 kcal)
Trial: 29360778
Drug: M504 (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M504 (70 g protein, 28 g carbohydrate, 12.4 g fat, 504 kcal)
Trial: 16632108
Drug: VDV3 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VDV3 vaccine
Trial: 12791632
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (25 mg Zn daily during the second half of pregnancy)
Trial: 10561270
Drug: Intensive consolidation
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive consolidation chemotherapy (CC)
Trial: 8565760
Drug: Sulglycotide 400
RxNorm normalized name: sulglicotide
DrugBank: Sulglicotide (DB13299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulglycotide 400 mg three times a day for one year
Trial: 2007672
Drug: Topical metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical metronidazole (1% cream), applied twice daily
Trial: 2007672
Drug: Oral tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tetracycline (250 mg, taken twice daily)
Trial: 6350473
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg acyclovir intravenously three times daily for five days
Trial: 20622200
Drug: Tecarfarin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tecarfarin (50 mg)
Trial: 20622200
Drug: Warfarin (17.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (17.5 mg)
Trial: 31773199
Drug: Bowel preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel preparation
Trial: 31773199
Drug: No bowel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No bowel preparation
Trial: 12928713
Drug: morphine 0.2
RxNorm normalized name: morphine 0.23 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 0.2 mg IT in addition to hyperbaric bupivacaine 10 mg IT
Trial: 12928713
Drug: hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyperbaric bupivacaine 10 mg IT
Trial: 11754675
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (200 microgram total dose, 2 puffs in each nostril once daily for 21 days)
Trial: 11754675
Drug: Placebo nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray (2 puffs in each nostril once daily for 21 days)
Trial: 9481097
Drug: Azathioprine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (1.5 mg/kg/day) with prednisolone (2 mg/kg on alternate days)
Trial: 9481097
Drug: Pulse intravenous
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse intravenous cyclophosphamide (500 mg/m2 body surface area monthly) with prednisolone (2 mg/kg on alternate days)
Trial: 3743615
Drug: oxprenolol Oros,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxprenolol Oros, 16/260 mg/day
Trial: 3743615
Drug: atenolol, 100
RxNorm normalized name: Atenolol, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol, 100 mg/day
Trial: 26709241
Drug: Glutamine supplementation
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine supplementation (21 g/day for 8 weeks)
Trial: 16920847
Drug: Lignan complex
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignan complex (500 mg/d of SDG)
Trial: 14682107
Drug: Postexcisional radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postexcisional radiation therapy
Trial: 14682107
Drug: No radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No radiation therapy (excision alone)
Trial: 8981490
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 (methylcobalamin; 0.5 mg/day intravenously for 11 days, followed by 2 mg x 3/day orally for 7 days)
Trial: 3921146
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment from a general practitioner
Trial: 3921146
Drug: Crossover behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover behavioural treatment from the nurse
Trial: 3921146
Drug: Dropped out
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dropped out or refused therapy
Trial: 31672711
Drug: Provision of
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provision of a progestogen-only pill (POP, desogestrel) plus rapid access to a local sexual and reproductive health (SRH) clinic.
Trial: 11146310
Drug: Calcitriol therapy
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcitriol therapy as a single weekly dose of 0.08 microg/kg b.w. (Group A)
Trial: 11146310
Drug: Calcitriol therapy
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcitriol therapy divided into two equal doses (Group B)
Trial: 11146310
Drug: Calcitriol therapy
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcitriol therapy divided into three doses (Group C)
Trial: 18623907
Drug: Meningitis B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningitis B vaccine (two doses)
Trial: 14572890
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg isosorbide mononitrate, given intravaginally 12 h before induction
Trial: 23488643
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg DHEA
Trial: 10372727
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg DHEA
Trial: 16483520
Drug: Telephone administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telephone administration of SF-36
Trial: 7983296
Drug: Face-to-face administration
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face administration of SF-36
Trial: 16483520
Drug: Self-administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of SF-36
Trial: 1417339
Drug: Indirect endolymphatic
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect endolymphatic therapy with bicillin‐3
Trial: 1417339
Drug: Routine penicillin
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine penicillin therapy
Trial: 6198058
Drug: Quadruple chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple chemotherapy
Trial: 29953575
Drug: Hypertonic saline-hydroxyethyl
RxNorm normalized name: Hydroxyethyl Cellulose
DrugBank: Hydroxyethyl cellulose (DB11602)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline-hydroxyethyl starch (HS-HES) solution
Trial: 27673385
Drug: Epinephrine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine (0.1 to 0.2 to 0.3 μg/kg/min)
Trial: 27673385
Drug: Dopamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine (10 to 15 to 20 μg/kg/min)
Trial: 25670057
Drug: Synergy™ drug-eluting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synergy™ drug-eluting stent (EES)
Trial: 1789096
Drug: Astigmatism treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astigmatism treatment
Trial: 28503750
Drug: Liraglutide 3
RxNorm normalized name: liraglutide 3.6 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 3 mg daily for 26 weeks
Trial: 27838115
Drug: Sevoflurane (2.5-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane (2.5-4 percent) inhalation in Group S (n=7)
Trial: 27838115
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion (1-2mg·kg-1·min-1) in Group P (n=7)
Trial: 17466854
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (n = 20) received 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub‐Tenon's space
Trial: 17466854
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (n = 20) received the same combination injected into the anterior sub‐Tenon's space
Trial: 15754633
Drug: Control (pharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (pharmacological treatment only)
Trial: 7586997
Drug: Med 15
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Med 15 (1.200 mg for 2 days, then 600 mg for 13 days)
Trial: 7586997
Drug: Piroxicam (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (same dosage regimen as Med 15)
Trial: 6986027
Drug: Antacid (Mylanta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid (Mylanta II, 30 ml every hour)
Trial: 6986027
Drug: Cimetidine with
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine with antacid titration
Trial: 23964752
Drug: DDEA 1.16%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDEA 1.16% gel (2 g, 4x/day, for 5 days)
Trial: 21423115
Drug: Vasoactive, antioxidant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoactive, antioxidant treatment and neuromidin (15 mg in solution for 10 days, then 20 mg three times a day for 2 months)
Trial: 21423115
Drug: Vasoactive and
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoactive and antioxidant treatment
Trial: 19684171
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of spread with a target dose of 1 x 10(9) CFU of L. reuteri DSM 17938
Trial: 19684171
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of spread with a target dose of 5 x 10(9) CFU of L. rhamnosus GG
Trial: 19684171
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of placebo spread
Trial: 11448297
Drug: Sertraline therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline therapy
Trial: 11020092
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of exercise and sertraline
Trial: 9432270
Drug: Bovine pericardium
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bovine pericardium patch angioplasty
Trial: 1469180
Drug: Midazolam (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (continuous infusion of 0.02‐0.20 mg/kg/h)
Trial: 6325909
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated Oka/Merck varicella vaccine